Sexual health in hematopoietic stem cell transplant recipients

  • Zhuoyan Li
    Department of Medicine Vanderbilt University Medical Center Nashville Tennessee
  • Prerna Mewawalla
    Department of Hematology Western Pennsylvania Cancer Institute Pittsburgh Pennsylvania
  • Pamela Stratton
    Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health Bethesda Maryland
  • Agnes S.M. Yong
    Department of Haematology, SA Pathology, and School of Medicine University of Adelaide Adelaide South Australia Australia
  • Bronwen E. Shaw
    Center for International Blood and Marrow Transplant Research Froedtert and the Medical College of Wisconsin Milwaukee Wisconsin
  • Shahrukh Hashmi
    Division of Hematology Mayo Clinic Rochester Minnesota
  • Madan Jagasia
    Hematology and Stem Cell Transplantation Section, Division of Hematology/Oncology, Department of Medicine Vanderbilt University Medical Center and Veterans Affairs Medical Center Nashville Tennessee
  • Mohamad Mohty
    INSERM (National Institute of Health and Medical Research) 938 Paris France
  • Navneet S. Majhail
    Blood and Marrow Transplant Program Cleveland Clinic Cleveland Ohio
  • Bipin N. Savani
    Hematology and Stem Cell Transplantation Section, Division of Hematology/Oncology, Department of Medicine Vanderbilt University Medical Center and Veterans Affairs Medical Center Nashville Tennessee
  • Alicia Rovó
    Department of Hematology University Hospital of Bern Bern Switzerland

抄録

<jats:p>Hematopoietic stem cell transplantation (HSCT) plays a central role in patients with malignant and, increasingly, nonmalignant conditions. As the number of transplants increases and the survival rate improves, long‐term complications are important to recognize and treat to maintain quality of life. Sexual dysfunction is a commonly described but relatively often underestimated complication after HSCT. Conditioning regimens, generalized or genital graft‐versus‐host disease, medications, and cardiovascular complications as well as psychosocial problems are known to contribute significantly to physical and psychological sexual dysfunction. Moreover, it is often a difficult topic for patients, their significant others, and health care providers to discuss. Early recognition and management of sexual dysfunction after HSCT can lead to improved quality of life and outcomes for patients and their partners. This review focuses on the risk factors for and treatment of sexual dysfunction after transplantation and provides guidance concerning how to approach and manage a patient with sexual dysfunction after HSCT. <jats:bold><jats:italic>Cancer</jats:italic> 2015;121:4124–4131.</jats:bold> © <jats:italic>2015 American Cancer Society</jats:italic>.</jats:p>

収録刊行物

  • Cancer

    Cancer 121 (23), 4124-4131, 2015-09-15

    Wiley

被引用文献 (4)*注記

もっと見る

問題の指摘

ページトップへ